Tauns Laboratories Inc

Tauns Laboratories Inc has a liquidity position with a current ratio of 1.62 and cash and equivalents of ¥9,266.63 million, but free cash flow is negative at -¥872.97 million, indicating capital outflows. The debt-to-equity ratio is 0.83, suggesting moderate leverage, and total liabilities amount to ¥19,097.62 million. Profitability metrics show a return on equity of 36.26% and a return on assets of 17.3%, both exceeding typical thresholds for the Medical Equipment, Supplies & Distribution industry, indicating strong returns relative to equity and asset base. The company's operating income of ¥8,243.58 million and net income of ¥6,315.41 million reflect robust performance. The company operates in a single business segment, in vitro diagnostic products, with no disclosed geographic revenue breakdown. This lack of segmentation data limits visibility into geographic exposure and potential concentration risks. Growth trajectory is not explicitly quantified in the input data, but the company's recent performance suggests a stable or growing revenue base. Analysts have set a mean price target of ¥450.00, with a median of ¥450.00 and a high of ¥490.00, indicating moderate optimism. Risk factors include a medium liquidity risk due to negative net cash after subtracting total debt. Dilution risk is assessed as low, with no near-term pressure expected. The company's capital structure and financial flexibility are key areas to monitor for potential dilution or liquidity stress. Recent events include analyst price targets and a single "Hold" recommendation, with no strong buy or buy ratings. This suggests a cautious outlook from the investment community, with limited upside potential in the near term.